Katharina Zimmermann

TL;DR: Compared with nTregs, A2‐CAR Tregs exhibited superior control of strong allospecific immune responses in vitro and in humanized mouse models, and have great potential for incorporation into clinical trials of Treg‐supported weaning after allogeneic transplantation.

TL;DR: The data demonstrate that the converted, insulin-specific CAR Tregs (cTregs) were functional stable, suppressive and long-lived in vivo, and a proof of concept for both redirection of T cell specificity and conversion of Teffs to cT Regs.

TL;DR: It is shown that T cells containing the “all-in-one” vector system secrete the immunomodulatory cytokines interleukin (IL)12 or IL18 upon co-cultivation with primary human GD2+ tumor cells, resulting in enhanced effector cell properties and increased monocyte recruitment, highlighting the potential of the system to simplify application of TRUCK-modified T cells in solid tumor therapy.

TL;DR: It is reported that latency‐associated peptide (LAP) and glycoprotein A repetitions predominant (GARP) can identify human Ag‐specific Treg cells, which could have a high therapeutic potential for the control of alloimmune, autoimmune, and allergic immune responses in patients.

TL;DR: Human umbilical cord maintains a microenvironment for the long-term induction of polyclonal and immune inhibitory active MSCs for months and would offer the possibility to drastically increase the number of therapeutically applicable M SCs for a substantial amount of patients.